These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6609483)

  • 21. Alpha-1-antitrypsin phenotypes in patients with ankylosing spondylitis.
    Sierakowski S; Chwiećko J; Kita K
    Rocz Akad Med Bialymst; 2001; 46():54-9. PubMed ID: 11780580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum concentration of IgA1 and IgA2 subclasses in ankylosing spondylarthritis].
    Hrncír Z; Tichý M
    Cas Lek Cesk; 1985 Nov; 124(47):1461-2. PubMed ID: 4064097
    [No Abstract]   [Full Text] [Related]  

  • 23. Alpha-1-antitrypsin phenotypes and rheumatic diseases.
    Sjöblom KG; Wollheim FA
    Lancet; 1977 Jul; 2(8027):41-2. PubMed ID: 69130
    [No Abstract]   [Full Text] [Related]  

  • 24. [Importance of main classes serum immunoglobulin level determination in ankylosing spondylarthritis].
    Rovenský J; Zitnan D; Svec V; Cebecauer L
    Fysiatr Revmatol Vestn; 1975 Apr; 53(2):100-4. PubMed ID: 1169203
    [No Abstract]   [Full Text] [Related]  

  • 25. [Determination of C-reactive protein in heart surgery: importance of postoperative monitoring of complications].
    Gaspardone A; Ciavolella M; Carlizzi G; Xagoraris V; Romeo F; Gioffrè PA
    Cardiologia; 1982 Dec; 27(12):1121-32. PubMed ID: 6985434
    [No Abstract]   [Full Text] [Related]  

  • 26. [Changes in humoral immunity in the serum in ankylosing spondyloarthritis].
    Hrncír Z; Krupar V; Simsa J; Tichý M
    Vnitr Lek; 1983 Jul; 29(7):648-56. PubMed ID: 6193638
    [No Abstract]   [Full Text] [Related]  

  • 27. The in-vivo metabolism of C3 in ankylosing spondylitis.
    Brinch L; Vinje O; Teisberg P; Mellbye OJ; Aakesson I
    Ann Rheum Dis; 1982 Feb; 41(1):86-9. PubMed ID: 7065734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The significance of immunologic changes in the serum for the laboratory evaluation of immunologic activity in ankylosing spondylitis].
    Hrncír Z; Krupar V; Simsa J; Tichý M
    Cas Lek Cesk; 1985 Apr; 124(14):431-3. PubMed ID: 4005919
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum protein markers in ankylosing spondylitis.
    Rantapää Dahlqvist S; Beckman L
    Hum Hered; 1987; 37(6):354-8. PubMed ID: 3500111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis.
    Raffeiner B; Dejaco C; Duftner C; Kullich W; Goldberger C; Vega SC; Keller M; Grubeck-Loebenstein B; Schirmer M
    Arthritis Res Ther; 2005; 7(6):R1412-20. PubMed ID: 16277694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein oxidation status in patients with ankylosing spondylitis.
    Yazici C; Köse K; Calis M; Kuzugüden S; Kirnap M
    Rheumatology (Oxford); 2004 Oct; 43(10):1235-9. PubMed ID: 15292529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunologic status of patients with selected connective tissue diseases].
    Swierczyńska Z; Woźniczko-Orłowska G; Luft S; Rdułtowska H; Kosowska E; Bujalska H; Rogozińska E; Zabek J
    Reumatologia; 1983; 21(1):15-24. PubMed ID: 6648068
    [No Abstract]   [Full Text] [Related]  

  • 33. [Autoantibodies against joint and prostatic antigen in spondylarthritis ankylopoetica].
    Rössner B; Wessel G; Pannenburg G; Lehmann M
    Z Gesamte Inn Med; 1974 Feb; 29(4):152-5. PubMed ID: 4209576
    [No Abstract]   [Full Text] [Related]  

  • 34. [Immunologic disorders in ankylosing spondylitis].
    Sadovska-Vroblevska M
    Ter Arkh; 1981; 53(7):22-5. PubMed ID: 6794171
    [No Abstract]   [Full Text] [Related]  

  • 35. [Role of blood proteins and sialic acids in the reactivity of patients with herpetic keratitis].
    Ul'danov GA; Kaĭnarbaeva KA; Zavadskaia IuS
    Oftalmol Zh; 1983; 38(3):172-5. PubMed ID: 6621989
    [No Abstract]   [Full Text] [Related]  

  • 36. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis.
    Lange U; Teichmann J; Stracke H
    Eur J Med Res; 2000 Dec; 5(12):507-11. PubMed ID: 11147993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunofluorescence studies on kidney biopsies in ankylosing spondylitis.
    Linder E; Pasternack A
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1970; 78(4):517-25. PubMed ID: 4922255
    [No Abstract]   [Full Text] [Related]  

  • 38. [Changes in pulmonary ventilation and respiratory mechanics in patients with ankylosing spondylarthritis].
    Král J; Felkel H
    Cas Lek Cesk; 1984 Mar; 123(9):259-64. PubMed ID: 6705028
    [No Abstract]   [Full Text] [Related]  

  • 39. Circulating levels of sialic acid and glycosaminoglycans: a diagnostic test for ankylosing spondylitis.
    Susheela AK; Das TK; Khurana JS; Jayaswal A; Dave PK
    Ann Rheum Dis; 1988 Oct; 47(10):833-7. PubMed ID: 2973770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ankylosing spondylitis in Japan.
    Mitsui H; Sonozaki H
    Ryumachi; 1981; 21 Suppl():45-9. PubMed ID: 7344134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.